Hypoxia Inducible Factor 1 Alpha - Pipeline Review, H1 2017

  • ID: 4311852
  • Drug Pipelines
  • 79 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CASI Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • InterMed Discovery GmbH
  • NewLink Genetics Corp
  • OncoImmune Inc
  • Peloton Therapeutics Inc
  • MORE
Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Pipeline Review, H1 2017

Summary:

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) pipeline Target constitutes close to 16 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Hypoxia Inducible Factor 1 Alpha - Pipeline Review, H1 2017, outlays comprehensive information on the Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Hypoxia-inducible factor 1-alpha is a subunit of a heterodimeric transcription factor encoded by the HIF1A gene. It plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. It activates the transcription of erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor and HILPDA under hypoxia condition. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 5 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Cardiovascular, Dermatology, Metabolic Disorders and Ophthalmology which include indications Hepatocellular Carcinoma, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Diabetic Foot Ulcers, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Graft Versus Host Disease (GVHD), Ischemia, Lung Cancer, Melanoma, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Small Cell Lung Cancer, Pancreatic Cancer, Parkinson's Disease, Peritoneal Cancer, Rectal Cancer, Rheumatoid Arthritis, Small-Cell Lung Cancer and Wounds.

Furthermore, this report also reviewsalso reviews key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)
  • The report reviews Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • CASI Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • InterMed Discovery GmbH
  • NewLink Genetics Corp
  • OncoImmune Inc
  • Peloton Therapeutics Inc
  • MORE
  1. Introduction
  2. Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Overview
  3. Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Companies Involved in Therapeutics Development
  14. CASI Pharmaceuticals Inc
  15. Daiichi Sankyo Company Ltd
  16. F. Hoffmann-La Roche Ltd
  17. InterMed Discovery GmbH
  18. NewLink Genetics Corp
  19. OncoImmune Inc
  20. Peloton Therapeutics Inc
  21. RXi Pharmaceuticals Corp
  22. Sorrento Therapeutics Inc
  23. Vascular Biogenics Ltd
  24. Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Drug Profiles
  25. A-503451A - Drug Profile
  26. Product Description
  27. Mechanism Of Action
  28. R&D Progress
  29. Antisense RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Oncology - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. BC-001 - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. CASI-2ME2 - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. CRLX-101 - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. Echinomycin - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile
  50. Product Description
  51. Mechanism Of Action
  52. R&D Progress
  53. HS-1793 - Drug Profile
  54. Product Description
  55. Mechanism Of Action
  56. R&D Progress
  57. IMD-026259 - Drug Profile
  58. Product Description
  59. Mechanism Of Action
  60. R&D Progress
  61. KCN-1 - Drug Profile
  62. Product Description
  63. Mechanism Of Action
  64. R&D Progress
  65. MPT-0B098 - Drug Profile
  66. Product Description
  67. Mechanism Of Action
  68. R&D Progress
  69. RG-6061 - Drug Profile
  70. Product Description
  71. Mechanism Of Action
  72. R&D Progress
  73. Small Molecules to Inhibit HIF-1 Alpha for Oncology - Drug Profile
  74. Product Description
  75. Mechanism Of Action
  76. R&D Progress
  77. SR-16388 - Drug Profile
  78. Product Description
  79. Mechanism Of Action
  80. R&D Progress
  81. TR-764 - Drug Profile
  82. Product Description
  83. Mechanism Of Action
  84. R&D Progress
  85. VB-411 - Drug Profile
  86. Product Description
  87. Mechanism Of Action
  88. R&D Progress
  89. Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Dormant Products
  90. Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Discontinued Products
  91. Hypoxia Inducible Factor 1 Alpha (ARNT Interacting Protein or Basic Helix Loop Helix PAS Protein MOP1 or Class E Basic Helix Loop Helix Protein 78 or Member Of PAS Protein 1 or PAS Domain Containing Protein 8 or HIF1A) - Product Development Milestones
  92. Featured News & Press Releases
  93. Oct 06, 2016: Cerulean Announces Clinical Data from CRLX101 Program at the 2016 European Society for Medical Oncology Annual Meeting
  94. Aug 18, 2016: Cerulean Announces Reduction in Force
  95. Aug 18, 2016: Cerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin Combination in Relapsed Renal Cell Carcinoma
  96. Jul 19, 2016: Cerulean Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer
  97. Jun 22, 2016: Cerulean Announces Publication in Cancer Research
  98. Jun 09, 2016: Cerulean Announces Manuscript Published in Annals of Oncology
  99. May 19, 2016: Cerulean Announces Oral Presentation on Phase 1b results of CRLX101 at Gynecologic Oncology 2016 Conference
  100. May 10, 2016: Cerulean Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRLX101 in Combination with LYNPARZA
  101. Apr 25, 2016: Cerulean Announces Oral Presentation of CRLX101 Clinical Data at Gynecologic Oncology 2016 Conference
  102. Apr 19, 2016: Cerulean Announces Presentation at 2016 American Association for Cancer Research Annual Meeting of Stage 1 Data from Phase 2 Trial in Platinum-Resistant Ovarian Cancer
  103. Mar 23, 2016: Cerulean Announces Publication Showing CRLX101 Localizes Selectively in Human Tumors, Sparing Adjacent Healthy Tissue
  104. Mar 16, 2016: Cerulean Announces Data Presentation at the 2016 American Association for Cancer Research Annual Meeting
  105. Nov 09, 2015: Cerulean Announces Data at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  106. Oct 27, 2015: Cerulean Announces Poster Presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  107. Oct 19, 2015: Cerulean Announces First Patient Dosed in Clinical Trial to Evaluate Weekly Dosing Schedule with CRLX101
  108. Appendix
  109. Methodology
  110. Coverage
  111. Secondary Research
  112. Primary Research
  113. Expert Panel Validation
  114. Contact Us
  115. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Companies, H1
  6. Products under Development by Companies, H1
  7. Products under Development by Companies, H1 2017 (Contd..1), H1
  8. Number of Products under Investigation by Universities/Institutes, H1
  9. Products under Investigation by Universities/Institutes, H1
  10. Number of Products by Stage and Mechanism of Actions, H1
  11. Number of Products by Stage and Route of Administration, H1
  12. Number of Products by Stage and Molecule Type, H1
  13. Pipeline by CASI Pharmaceuticals Inc, H1
  14. Pipeline by Daiichi Sankyo Company Ltd, H1
  15. Pipeline by F. Hoffmann-La Roche Ltd, H1
  16. Pipeline by InterMed Discovery GmbH, H1
  17. Pipeline by NewLink Genetics Corp, H1
  18. Pipeline by OncoImmune Inc, H1
  19. Pipeline by Peloton Therapeutics Inc, H1
  20. Pipeline by RXi Pharmaceuticals Corp, H1
  21. Pipeline by Sorrento Therapeutics Inc, H1
  22. Pipeline by Vascular Biogenics Ltd, H1
  23. Dormant Products, H1
  24. Dormant Products, H1 2017 (Contd..1), H1
  25. Dormant Products, H1 2017 (Contd..2), H1
  26. Discontinued Products, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Mechanism of Actions, H1
  5. Number of Products by Stage and Mechanism of Actions, H1
  6. Number of Products by Routes of Administration, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • CASI Pharmaceuticals Inc
  • Daiichi Sankyo Company Ltd
  • F. Hoffmann-La Roche Ltd
  • InterMed Discovery GmbH
  • NewLink Genetics Corp
  • OncoImmune Inc
  • Peloton Therapeutics Inc
  • RXi Pharmaceuticals Corp
  • Sorrento Therapeutics Inc
  • Vascular Biogenics Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll